Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical tacrolimus.

S J Frankel1, F A Kerdel

  • 1Department of Dermatology, University of Miami School Of Medicine, Miami, Florida, USA.

Skin Therapy Letter
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Tacrolimus is a potent immunosuppressant that blocks Interleukin-2 (IL-2) production and T-cell proliferation. It is now approved as an ointment for treating atopic dermatitis, expanding its therapeutic applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Journal of the European Academy of Dermatology and Venereology : JEADV·2016
Same author

[Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].

Actas dermo-sifiliograficas·2011
Same author

[Type I cryoglobulinemia with a fatal outcome].

Actas dermo-sifiliograficas·2011
Same author

Biological agents in the treatment of psoriasis.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2008
Same author

Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2008
Same author

Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.

International journal of dermatology·2004
Same journal

Exosomes in Dermatology.

Skin therapy letter·2026
Same journal

Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.

Skin therapy letter·2026
Same journal

Erratum to: Deuruxolitinib for Alopecia Areata.

Skin therapy letter·2026
Same journal

Advances in the Management of Hyperhidrosis.

Skin therapy letter·2026
Same journal

Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa.

Skin therapy letter·2026
Same journal

Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis.

Skin therapy letter·2026
See all related articles

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Tacrolimus is a potent immunosuppressive drug.
  • It functions by blocking Interleukin-2 (IL-2) and inhibiting T-cell proliferation.
  • Initially developed for organ transplantation, its potential in treating inflammatory skin conditions is under investigation.

Purpose of the Study:

  • To highlight the expanded therapeutic applications of tacrolimus.
  • To discuss the recent FDA approval of topical tacrolimus for atopic dermatitis.

Main Methods:

  • Review of tacrolimus's mechanism of action.
  • Summary of its clinical development for dermatological conditions.
  • Mention of the US FDA approval for atopic dermatitis treatment.

Related Experiment Videos

Main Results:

  • Tacrolimus effectively suppresses the immune response by inhibiting IL-2 production and T-cell proliferation.
  • Topical tacrolimus (Protopic®) has received US FDA approval for atopic dermatitis treatment.

Conclusions:

  • Tacrolimus is a valuable immunosuppressant with demonstrated efficacy in inflammatory dermatoses.
  • The approval of topical tacrolimus offers a new treatment option for patients with atopic dermatitis.